(Reuters) -Cipla, India’s No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong demand for its generic respiratory drugs.
The company’s consolidated net profit came in at 12.22 billion rupees ($143.5 million) in the January-March period. Analysts, on average, expected 10.24 billion rupees, per data compiled by LSEG.
($1 = 85.1560 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru)
